Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review

被引：28

作者：

Suraweera, Duminda ^{[1
]}

Rahal, Harman ^{[2
]}

Jimenez, Melissa ^{[3
]}

Viramontes, Matthew ^{[3
]}

Choi, Gina ^{[3
]}

Saab, Sammy ^{[2
,3
]}

机构：

[1] Olive View Med Ctr, Dept Med, Sylmar, CA USA

[2] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA

[3] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA

来源：

LIVER INTERNATIONAL | 2017年 / 37卷 / 12期

关键词：

fenofibrate; non-responder; pharmacology; primary biliary cholangitis; ursodeoxycholic acid; BIOCHEMICAL RESPONSE; CONTROLLED-TRIAL; MYCOPHENOLATE-MOFETIL; FENOFIBRATE TREATMENT; COMBINATION THERAPY; INCOMPLETE RESPONSE; SUBOPTIMAL RESPONSE; OBETICHOLIC ACID; ORAL BUDESONIDE; END-POINTS;

D O I：

10.1111/liv.13477

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic cholestatic liver disease characterized by an immune mediated destruction of intrahepatic bile ducts. Ursodeoxycholic acid (UDCA) has been the primary medication for the treatment of PBC, resulting in improved liver tests, resolution of symptoms and increased transplant free survival. However, not all patients respond to UDCA. The aim of this systematic review is to provide an evidence based assessment of the medications that have been studied in patients who are refractory to UDCA. Methods: We performed a systematic literature search on MEDLINE and the Cochrane Database of Systematic Reviews of the published literature. A total of 23 articles fulfilling our inclusion criteria were found. Results: Several studies have shown an improvement in liver biochemistries with the use of obeticholic acid in conjunction with UDCA. Fibrates, including fenofibrate and bezafibrate, have evidence supporting benefit in this population but need more robust studies to confirm these observational results. Neither obeticholic acid nor fibrates have shown to increase transplant free survival. While there may be some benefit with methotrexate, colchicine, budesonide, mycophenolate mofetil and azathioprine, these findings were not consistent and the benefits were marginal. Further investigation is needed. Conclusion: In patients with PBC refractory to UDCA, obeticholic acid or a fibrate is a reasonable choice as an adjunctive treatment to UDCA. Further investigation with randomized controlled trials is needed to provide high quality evidence to formulate standardized therapies in this difficult to treat population.

引用

页码：1877 / 1886

页数：10

共 53 条

[41] A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis [J].

Nevens, F. ;

Andreone, P. ;

Mazzella, G. ;

Strasser, S. I. ;

Bowlus, C. ;

Invernizzi, P. ;

Drenth, J. P. H. ;

Pockros, P. J. ;

Regula, J. ;

Beuers, U. ;

Trauner, M. ;

Jones, D. E. ;

Floreani, A. ;

Hohenester, S. ;

Luketic, V. ;

Shiffman, M. ;

van Erpecum, K. J. ;

Vargas, V. ;

Vincent, C. ;

Hirschfield, G. M. ;

Shah, H. ;

Hansen, B. ;

Lindor, K. D. ;

Marschall, H-U ;

Kowdley, K. V. ;

Hooshmand-Rad, R. ;

Marmon, T. ;

Sheeron, S. ;

Pencek, R. ;

MacConell, L. ;

Pruzanski, M. ;

Shapiro, D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (07) :631-643

[42]

Ohira H, 2002, AM J GASTROENTEROL, V97, P2147

[43] Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid [J].

Parés, A ;

Caballería, L ;

Rodés, J .

GASTROENTEROLOGY, 2006, 130 (03) :715-720

[44] 6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity [J].

Pellicciari, R ;

Fiorucci, S ;

Camaioni, E ;

Clerici, C ;

Costantino, G ;

Maloney, PR ;

Morelli, A ;

Parks, DJ ;

Willson, TM .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3569-3572

[45]

Poupon RE, 1996, HEPATOLOGY, V24, P1098

[46] Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis [J].

Poupon, RE ;

Lindor, KD ;

CauchDudek, K ;

Dickson, ER ;

Poupon, R ;

Heathcote, EJ .

GASTROENTEROLOGY, 1997, 113 (03) :884-890

[47] A MULTICENTER, CONTROLLED TRIAL OF URSODIOL FOR THE TREATMENT OF PRIMARY BILIARY-CIRRHOSIS [J].

POUPON, RE ;

BALKAU, B ;

ESCHWEGE, E ;

POUPON, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (22) :1548-1554

[48] Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone [J].

Rabahi, N. ;

Chretien, Y. ;

Gaouar, F. ;

Wendum, D. ;

Serfaty, L. ;

Chazouilleres, O. ;

Corpechot, C. ;

Poupon, R. .

GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2010, 34 (4-5) :283-287

[49] Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid [J].

Stojakovic, Tatjana ;

Putz-Bankuti, Csilla ;

Fauler, Guenter ;

Scharnagl, Hubert ;

Wagner, Martin ;

Stadlbauer, Vanessa ;

Gurakuqi, Gerald ;

Stauber, Rudolf E. ;

Maerz, Winfried ;

Trauner, Michael .

HEPATOLOGY, 2007, 46 (03) :776-784

[50]

Suarez-Almazor M. E., 1996, COCHRANE DB SYST REV, P1, DOI [10.1002/14651858.CD001461, DOI 10.1002/14651858.CD001461]

← 1 2 3 4 5 6 →